EMPLOYMENT AGREEMENTEmployment Agreement • August 18th, 2011 • ImmunoCellular Therapeutics, Ltd. • Pharmaceutical preparations • California
Contract Type FiledAugust 18th, 2011 Company Industry JurisdictionThis Employment Agreement (this “Agreement”) is made as of the 10th day of May, 2011, by and between ImmunoCellular Therapeutics, Ltd., a Delaware corporation (the “Corporation”), and Dr. James Bender (hereinafter called “Executive”).
EMPLOYMENT AGREEMENTEmployment Agreement • August 18th, 2011 • ImmunoCellular Therapeutics, Ltd. • Pharmaceutical preparations • California
Contract Type FiledAugust 18th, 2011 Company Industry JurisdictionThis Employment Agreement (this “Agreement”) is made as of the 10th day of May, 2011, by and between ImmunoCellular Therapeutics, Ltd., a Delaware corporation (the “Corporation”), and Dr. Manish Singh (hereinafter called “Executive”).
EMPLOYMENT AGREEMENTEmployment Agreement • March 31st, 2010 • ImmunoCellular Therapeutics, Ltd. • Pharmaceutical preparations • California
Contract Type FiledMarch 31st, 2010 Company Industry JurisdictionThis Employment Agreement (this “Agreement”) is made as of the 18th day of February, 2010, by and between ImmunoCellular Therapeutics, Ltd., a Delaware corporation (the “Corporation”), and Dr. Manish Singh (hereinafter called “Executive”).
EMPLOYMENT AGREEMENTEmployment Agreement • March 30th, 2009 • ImmunoCellular Therapeutics, Ltd. • Pharmaceutical preparations • California
Contract Type FiledMarch 30th, 2009 Company Industry JurisdictionThis Employment Agreement (this “Agreement”) is made as of the 18th day of February, 2009, by and between ImmunoCellular Therapeutics, Ltd., a Delaware corporation (the “Corporation”), and Dr. Manish Singh (hereinafter called “Executive”).
EMPLOYMENT AGREEMENTEmployment Agreement • March 25th, 2008 • ImmunoCellular Therapeutics, Ltd. • Biological products, (no disgnostic substances) • California
Contract Type FiledMarch 25th, 2008 Company Industry JurisdictionThis Employment Agreement (this “Agreement”) is made as of the 18th day of February, 2008, by and between ImmunoCellular Therapeutics, Ltd., a Delaware corporation (the “Corporation”), and Dr. Manish Singh (hereinafter called “Executive”).